MMCM
EXAS

Murphy & Mullick Capital Management’s Exact Sciences EXAS Stock Holding History

Murphy & Mullick Capital Management’s Portfolio EXAS Stock Details EXAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6
Closed -$260 – 680
2025
Q1 		$260 Hold
6
– – ﹤0.01% 647
2024
Q4 		$337 Buy
+6
New +$373 ﹤0.01% 633

Other funds holding EXAS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Murphy & Mullick Capital Management's EXAS Position: Q2 2025 in Review

Murphy & Mullick Capital Management sold out of Exact Sciences (EXAS) in Q2 2025, closing a stake of 6 shares — an estimated $260 sold.

Murphy & Mullick Capital Management first reported a position in EXAS in Q4 2024 and held it in 2 quarters. The position peaked at $337 in Q4 2024. 558 funds tracked by Wall St. Rank hold EXAS as of Q2 2025.

  • Murphy & Mullick Capital Management reported no remaining Exact Sciences position as of Q2 2025 after selling out during the quarter.
  • Murphy & Mullick Capital Management sold 6 Exact Sciences shares in Q2 2025, an estimated $260.
  • Murphy & Mullick Capital Management first reported a position in Exact Sciences in Q4 2024 and held it in 2 quarters.
  • Murphy & Mullick Capital Management's Exact Sciences position peaked at $337 in Q4 2024.
  • 558 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2025.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.